Cargando…

Primer on Biomarker Discovery in Cardio-Oncology: Application of Omics Technologies

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Rhee, June-Wha, Ky, Bonnie, Armenian, Saro H., Yancy, Clyde W., Wu, Joseph C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Primers in Cardio-Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560982/ https://www.ncbi.nlm.nih.gov/pubmed/33073248 http://dx.doi.org/10.1016/j.jaccao.2020.07.006

Ejemplares similares

Cardiac Computed Tomography in Cardio-Oncology: JACC: CardioOncology Primer
por: Lopez-Mattei, Juan C., et al.
Publicado: (2021)

Racial and Ethnic Disparities in Cardio-Oncology: A Call to Action
por: Fazal, Muhammad, et al.
Publicado: (2021)

Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer
por: Ganatra, Sarju, et al.
Publicado: (2022)

The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer
por: Zhang, Lili, et al.
Publicado: (2021)

Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: JACC: CardioOncology Primer
por: Henriksen, Peter A., et al.
Publicado: (2023)

Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity: JACC: CardioOncology Primer
por: Kok, Cindy Y., et al.
Publicado: (2021)

Strain Imaging in Cardio-Oncology
por: Liu, Jennifer E., et al.
Publicado: (2020)

How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations
por: Kambhampati, Swetha, et al.
Publicado: (2023)

Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology
por: Porter, Charles, et al.
Publicado: (2022)

Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization
por: O’Quinn, Rupal, et al.
Publicado: (2021)

Developing a Model for Cross-Institutional Educational Collaborations: The Chicago Cardio-Oncology Consortium (CCC) Experience
por: Minga, Iva, et al.
Publicado: (2023)

Cardio-oncology in 2022
por: Dobson, Rebecca
Publicado: (2023)

The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus
por: Gent, David G, et al.
Publicado: (2023)

Cardio‐Oncology at the Beginning of a New Decade
por: Grumbach, Isabella M.
Publicado: (2020)

Reverse Cardio‐Oncology: Cancer Development in Patients With Cardiovascular Disease
por: Aboumsallem, Joseph Pierre, et al.
Publicado: (2020)

How to Perform Pericardiocentesis in Cancer Patients With Thrombocytopenia: A Single-Center Experience
por: Jacob, Robin, et al.
Publicado: (2021)

Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
por: Feng, Kent Y., et al.
Publicado: (2019)

CAR T Cell Therapy–Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?
por: Ghosh, Arjun K., et al.
Publicado: (2020)

CARTing Away Cardiac Fibrosis
por: Epstein, Jonathan A.
Publicado: (2020)

Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics: What Is the Evidence?
por: Kamphuis, Janine A.M., et al.
Publicado: (2019)

Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis
por: Witteles, Ronald M.
Publicado: (2021)

How to Screen for Monoclonal Gammopathy in Patients With a Suspected Amyloidosis
por: Rubinstein, Samuel M., et al.
Publicado: (2021)

What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?
por: Thuny, Franck, et al.
Publicado: (2022)

The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity
por: Huang, Yuhsin Vivian, et al.
Publicado: (2022)

Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction
por: Demissei, Biniyam G., et al.
Publicado: (2020)

Dyspnoea in Oncological Patients: A Brain Teaser
por: Keramida, Kalliopi, et al.
Publicado: (2023)

COVID-19 and Katrina: recalcitrant racial disparities
por: Van Spall, Harriette G C, et al.
Publicado: (2020)

Cardio-oncology Training in the COVID-19 Era
por: Feldman, Stephanie, et al.
Publicado: (2021)

Disparities in Cardio-oncology: Effects On Outcomes and Opportunities for Improvement
por: Ahmad, Javaria, et al.
Publicado: (2022)

Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism
por: Zhao, Yiqi, et al.
Publicado: (2023)

Proceedings From the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology
por: Lenihan, Daniel J., et al.
Publicado: (2019)

Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology
por: Joolharzadeh, Pouya, et al.
Publicado: (2023)

COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
por: Ky, Bonnie, et al.
Publicado: (2020)

COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
por: Ky, Bonnie, et al.
Publicado: (2020)

The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population
por: Asokan, Ishan, et al.
Publicado: (2020)

Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building
por: Sadler, Diego, et al.
Publicado: (2021)

Strategies for Cardio-Oncology Care During the COVID-19 Pandemic
por: Abraham, Sonu, et al.
Publicado: (2022)

Innovations in Cardio-oncology Resulting from the COVID-19 Pandemic
por: Kondapalli, Lavanya, et al.
Publicado: (2022)

Long‐term survivors of early breast cancer treated with chemotherapy are characterized by a pro‐inflammatory biomarker profile compared to matched controls
por: Tromp, Jasper, et al.
Publicado: (2020)

The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic
por: Kwan, Jennifer M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ct10hh9iteu438aopnc8d8ov3o